4.7 Article

Multimerization of the GATA4 transcription factor regulates transcriptional activity and cardiomyocyte hypertrophic response

期刊

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
卷 18, 期 3, 页码 1079-1095

出版社

IVYSPRING INT PUBL
DOI: 10.7150/ijbs.65664

关键词

GATA4; Multimerization; Acetylation; Cardiomyocyte; Hypertrophy

资金

  1. Tokyo Biochemical Research Foundation
  2. Japan Heart Foundation
  3. Japan Science and Technology Agency [24890191, 15K09108, 26460071]
  4. Takeda Science Foundation
  5. Cardiovascular Research Fund
  6. Grants-in-Aid for Scientific Research [26460071, 15K09108, 24890191] Funding Source: KAKEN

向作者/读者索取更多资源

This study reveals the significance of GATA4 homomultimerization in cardiac hypertrophy, with the acetylation by p300 promoting the multimerization and DNA binding activity of GATA4. Inhibition of GATA4 multimerization suppresses phenylephrine-induced hypertrophic response in cardiomyocytes.
The activation of the GATA-binding factor 4 (GATA4) transcription factor induces cardiac hypertrophy and heart failure. The multimerization of transcription factors often plays an important role in the regulation of transcriptional activity. Here, we report that the GATA4 transcription factor forms a homomultimer and that residues 308-326 of GATA4 are necessary for its multimerization. The acetylation of GATA4 by the transcriptional co-activator p300 induces the multimerization of GATA4 and activates its DNA binding activity. In addition, we found that the suppression of GATA4 multimerization did not reduce its acetylation, but repressed GATA4/p300-induced gene transcription. Furthermore, the inhibition of GATA4 multimerization suppressed phenylephrine (PE)-induced hypertrophic response in cardiomyocytes. This study demonstrates that the multimerization of GATA4 during the p300-induced acetylation of GATA4 activates the transcription of hypertrophic response genes, which leads to cardiomyocyte hypertrophy. Therefore, the inhibition of GATA4 homomultimerization could serve as a potential therapeutic strategy for the development of novel drugs against heart failure.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据